IN8bio to Present Clinical and Preclinical Data from Gamma-Delta T Cell Platform at Upcoming Scientific Conferences

Core Insights - IN8bio, Inc. is a clinical-stage biopharmaceutical company focused on developing gamma-delta T cell therapies for cancer and autoimmune diseases, and it will present new clinical and preclinical data at several upcoming scientific conferences [1][2] Upcoming Presentations - At the American Association for Cancer Research (AACR) 2025, IN8bio will present a poster on a novel gamma-delta T cell engager platform for cancer immunotherapy on April 30, 2025 [3] - At the International Society for Cell & Gene Therapy (ISCT) 2025, IN8bio will deliver an oral presentation on the manufacturing process of donor-derived allogeneic ex vivo expanded and activated gamma-delta T cell products on May 9, 2025, and a poster on the implementation of an electronic quality management system on May 8, 2025 [4] - At the American Society of Gene & Cell Therapy (ASGCT) 2025 Conference, IN8bio will present a poster on the INB-600 T cell engager platform on May 15, 2025, and an oral presentation on the molecular signature of expanded gamma-delta T cell products on May 17, 2025 [5] - At the American Society of Clinical Oncology (ASCO) 2025, IN8bio will present an oral presentation on the Phase 1 study of gene-modified autologous gamma-delta T cells in newly diagnosed glioblastoma multiforme patients on May 30, 2025 [6][7] Company Overview - IN8bio is developing gamma-delta T cell-based immunotherapies targeting cancer and autoimmune diseases, with its lead program, INB-100, focused on acute myeloid leukemia using haplo-matched allogeneic gamma-delta T cells post-hematopoietic stem cell transplant [7]